PMID- 34196150
OWN - NLM
STAT- MEDLINE
DCOM- 20220211
LR  - 20220211
IS  - 1314-2143 (Electronic)
IS  - 0204-8043 (Linking)
VI  - 63
IP  - 3
DP  - 2021 Jun 30
TI  - A pilot study reveals the potential of miR-31-3p and miR-196a-5p as non-invasive 
      biomarkers in advanced laryngeal cancer.
PG  - 355-364
LID - 10.3897/folmed.63.e55346 [doi]
AB  - INTRODUCTION: Recently, miRNAs have become popular molecules used as non-invasive 
      biomarkers in cancer diseases. AIM: The aim of the study was to explore the 
      expression of four miRNAs isoforms: miR-31-3p, miR-196a-5p, miR-210-3p and 
      miR-424-5p in plasma and tissue samples from patients with advanced laryngeal 
      squamous cell carcinoma (LSCC) and healthy controls. MATERIALS AND METHODS: 
      Fresh-frozen tumour and normal laryngeal tissue as well as plasma samples were 
      obtained from 22 patients diagnosed with advanced LSCC. The control group 
      included plasma samples from 21 cancer-free volunteers. Total RNA (including 
      miRNAs) extraction, reverse transcription and real time qPCR were the laboratory 
      techniques used in the study. The obtained results were analyzed using SPSS 
      software v. 23. RESULTS: We found that miR-31-3p, miR-196a-5p, and miR-210-3p 
      levels were significantly elevated in laryngeal tumour tissue, but only the 
      levels of miR-31-3p and miR-196a-5p were significantly upregulated in the plasma 
      LSCC target group. Positive correlation was obtained for miR-31-3p (rs=0.443, 
      p=0.039) and miR-196a-5p (rs=0.548; p=0.008) between plasma and adjacent tumour 
      tissue LSCC samples. ROC analyses were used to evaluate the discriminative power 
      of both miRNAs alone and in combination. The combination of miR-31-3p and 
      miR-196a-5p showed best results with AUC=0.978 (95% CI: 0.945-1.000, p.
CI  - This is an open access article distributed under the terms of the Creative 
      Commons Attribution License (CC BY 4.0), which permits unrestricted use, 
      distribution, and reproduction in any medium, provided the original author and 
      source are credited.
FAU - Kyurkchiyan, Silva Garo
AU  - Kyurkchiyan SG
AD  - Medical University of Sofia, Sofia, Bulgaria.
FAU - Popov, Todor Miroslavov
AU  - Popov TM
AUID- ORCID: 0000-0002-8205-3573
AD  - Medical University of Sofia, Sofia, Bulgaria.
FAU - Shakola, Felitsiya
AU  - Shakola F
AD  - Medical University of Sofia, Sofia, Bulgaria.
FAU - Rangachev, Julian
AU  - Rangachev J
AD  - Medical University of Sofia, Sofia, Bulgaria.
FAU - Mitev, Vanyo Ivanov
AU  - Mitev VI
AD  - Medical University of Sofia, Sofia, Bulgaria.
FAU - Kaneva, Radka
AU  - Kaneva R
AD  - Medical University of Sofia, Sofia, Bulgaria.
LA  - eng
PT  - Journal Article
PL  - Bulgaria
TA  - Folia Med (Plovdiv)
JT  - Folia medica
JID - 2984761R
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MIRN31 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - Humans
MH  - *Laryngeal Neoplasms/genetics
MH  - MicroRNAs/genetics/*supply & distribution
MH  - Pilot Projects
MH  - Squamous Cell Carcinoma of Head and Neck
OTO - NOTNLM
OT  - LSCC
OT  - laryngeal squamous cell carcinoma
OT  - miRNAs
OT  - non-invasive biomarker
OT  - plasma
EDAT- 2021/07/02 06:00
MHDA- 2022/02/12 06:00
CRDT- 2021/07/01 07:32
PHST- 2020/06/11 00:00 [received]
PHST- 2020/08/11 00:00 [accepted]
PHST- 2021/07/01 07:32 [entrez]
PHST- 2021/07/02 06:00 [pubmed]
PHST- 2022/02/12 06:00 [medline]
AID - 10.3897/folmed.63.e55346 [doi]
PST - ppublish
SO  - Folia Med (Plovdiv). 2021 Jun 30;63(3):355-364. doi: 10.3897/folmed.63.e55346.